Tech Company Financing Transactions
GlobeImmune Funding Round
GlobeImmune closed a $34.3 million Series B funding round on 9/14/2005. Investors included Lilly Ventures, Adams Harkness Ventures and Biogen Idec.
Transaction Overview
Company Name
Announced On
9/14/2005
Transaction Type
Venture Equity
Amount
$34,300,000
Round
Series B
Investors
Lilly Ventures (Lead Investor) (Darren Carroll)
Proceeds Purpose
This funding will enable us to continue the development of our two lead clinical products, GI-4000 and GI-5005, evaluating the clinical utility of the Tarmogen technology in oncology and infectious disease.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1450 Infinite Dr.
Louisville, CO 80027
USA
Louisville, CO 80027
USA
Phone
Website
Email Address
Overview
GlobeImmune is developing Tarmogen product candidates to treat cancer and infectious diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Timothy Rodell
VP - Bus. Development
Kirk Christoffersen
VP - Finance
Jeffrey Dekker
Browse more venture capital transactions:
Prev: 9/14/2005: BladeLogic venture capital transaction
Next: 9/14/2005: Earnix venture capital transaction
Share this article
News on VC Transactions
We document all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs